AtriCure Earnings Call Highlights Growth Amid Headwinds

Atricure, Inc. ((ATRC)) has held its Q4 earnings call. Read on for the main highlights of the call.

AtriCure’s latest earnings call struck an optimistic tone, pairing double‑digit revenue growth and sharply higher profitability with visible momentum in key product lines. Management acknowledged real pressure in its minimally invasive Afib business and U.K. reimbursement, but emphasized strong cash generation, disciplined spending, and confidence in the long‑term growth and margin story.

Revenue Growth Outpaces Expectations

AtriCure delivered FY2025 revenue of $534.5 million, rising 14.9% on a reported basis and topping its original 11%–13% growth outlook. The beat underscores broad strength across the portfolio despite regional and segment headwinds, reinforcing management’s view that the core franchise remains in a solid growth phase.

Quarterly Momentum Supports Growth Narrative

Fourth‑quarter 2025 revenue reached $140.5 million, up 13.1% versus the prior‑year quarter and 12.1% in constant currency. Sales also improved sequentially, adding $6.2 million, or 4.6%, over Q3, suggesting demand stayed resilient into year‑end rather than fading after a strong first half.

Profitability Nearly Doubles Year Over Year

Adjusted EBITDA for 2025 climbed to $61.8 million from $31.1 million a year ago, a more than 90% increase that highlights growing operating leverage. In Q4, adjusted EBITDA improved to $19.9 million from $12.7 million, and the company swung to positive net income of $1.8 million compared with a $15.6 million loss in the prior‑year period.

Margins Firm Up and Cash Position Strengthens

Gross margin held at a healthy 75% for both the quarter and full year, expanding 45 basis points in Q4 and 29 basis points for 2025 versus 2024. Cash generation reached roughly $45 million for the year, leaving AtriCure with $167.4 million in cash and investments, giving the company ample flexibility to fund growth and weather near‑term volatility.

Pain Management Franchise Delivers Standout Growth

The pain management business was a star performer, with worldwide revenue up 33% for 2025 and 24% in Q4, driven by rapid adoption of cryoSPHERE MAX. AtriCure ended the year with about 500 U.S. accounts using cryoSPHERE MAX and has surpassed 100,000 patients treated with cryoSPHERE probes since their 2019 launch, signaling deepening clinical penetration.

Appendage Management Gains Powered by FLEX‑Mini

The left atrial appendage franchise posted 19% worldwide revenue growth for the year and 15% in Q4, led by strength in open procedures. U.S. open appendage management grew around 24%, while AtriClip FLEX‑Mini accounted for roughly 18% of global appendage revenue, with more than 300 active accounts purchasing the device.

Open Ablation and EnCompass Extend Leadership

Open ablation revenue grew more than 17% in both Q4 and the full year, reinforcing AtriCure’s strong position in surgical Afib treatment. The EnCompass Clamp was the primary growth engine, now present in over 830 accounts worldwide and contributing more than 60% of U.S. open ablation revenue.

Clinical and R&D Pipeline Hits Key Milestones

On the clinical front, the LeAAPS trial completed enrollment of about 6,573 patients across 137 sites and more than 500 surgeons, a major evidence‑building milestone. The company also launched the BoxX‑NoAF trial, initiated first‑in‑human dual‑energy EnCompass treatments, and rolled out AtriClip PRO Mini, cryoXT PRO, and cryoXT for pain and amputation indications.

Expense Discipline Supports Operating Leverage

Operating expenses rose 5.9% for the year, well below the 13% top‑line growth, reflecting tight cost control. SG&A climbed 6.7%, also lagging revenue, while R&D is set to moderate now that LeAAPS enrollment is complete, with management targeting low‑teens organic R&D growth in 2026 as overall operating leverage improves.

MIS/Hybrid Afib Segment Under Heavy Pressure

Not all segments are moving in the right direction, with the minimally invasive and hybrid Afib franchise facing substantial headwinds from rapid adoption of pulsed field ablation. U.S. MIS revenue fell 31.2% to $31.5 million in 2025, reflecting around $16 million of combined declines in MIS ablation and appendage devices, and further though moderating pressure is expected in 2026.

U.K. Reimbursement Issues Weigh on International Sales

International performance was dented by a sharp slowdown in the U.K., where NHS funding and reimbursement uncertainty disrupted what had been a fast‑growing market. The U.K. quarterly run rate dropped from about $4 million to a little over $1 million in Q4, creating a notable short‑term drag on overall revenue growth.

New Competition Emerges in Appendage Market

Management also flagged the recent entry of a major competitor into the clip market, adding a fresh competitive layer to the appendage segment. While the company has only modeled mild competitive pressure into its 2026 outlook, executives acknowledged this as a key dynamic that could influence near‑term market share and stock volatility.

R&D Costs and Cash Timing Create Near‑Term Noise

R&D spending remained elevated in 2025, growing about 11% excluding one‑time adjustments as costs for ongoing trials like BoxX‑NoAF continued. Management signaled an expected net cash burn in the first quarter of 2026 tied to annual variable compensation and share vesting, but anticipates a return to positive cash generation for the balance of the year.

Guidance and Long‑Term Targets Reinforced

AtriCure reaffirmed 2026 revenue guidance of $600–$610 million, implying 12%–14% growth, and an adjusted EBITDA range of $80–$82 million alongside modest EPS gains and continued cash generation after Q1. The outlook calls for slight margin expansion, SG&A growth below sales, MIS declines that moderate over time, pain management and open procedures leading growth, and steady progress toward a 2030 goal of about $1 billion in revenue and more than 20% adjusted EBITDA margin.

AtriCure’s earnings call painted the picture of a company balancing impressive growth and profitability gains with real but manageable headwinds. Investors will be watching whether the high‑growth pain, open ablation, and appendage franchises can continue to offset MIS pressures and international reimbursement issues, but management’s reaffirmed 2026 guidance and long‑term targets suggest confidence in the trajectory ahead.